Marvel Biosciences Corp., a life sciences company, primarily focuses on the discovery and the development of synthetic derivative compound of a known proven drug. The company's lead compound MB-204, a novel fluorinated derivative of Istradefylline, which is a clinically approved adenosine A2a receptor antagonist used for the treatment of Parkinson's disease. It targets diseases, such as depression, Alzheimer's disease, and liver fibrosis due to non-alcoholic steatohepatitis. The company has Collaboration agreement with FRAXA Research Foundation for the development of MB204. Marvel Biosciences Corp. is headquartered in Calgary, Canada.
0.1226 | |
0.1226 | |
- | |
0.1226 | |
0.1226 | |
0.0377-0.14 | |
5 649 K | |
44 786 K | |
0 | |
-0.0057 | |
0.497 |
No long-term obligations. The minimum period is one month only. No wait. You get an API key with instructions in a few seconds right after subscription.
Our 24/7 support would be happy to assist you via chat or email:
support@eodhistoricaldata.comVisit also: